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Abstract
Respiratory syncytial virus (RSV) is the leading cause of hospitalization due to respiratory illness among
infants and young children of industrialized countries. There is a lack of understanding of the severe disease
mechanisms as well as limited treatment options, none of which are fully satisfactory. This is partly due to lack
of a relevant animal model of perinatal RSV infection that mimics moderate to severe disease in infants. We
and others have shown mild disease in perinatal lambs with either a bovine or a human A2 strain of RSV. The
Memphis 37 clinical strain of human RSV has been used to produce mild to moderate upper respiratory
disease in healthy adult volunteers. We hypothesized that the Memphis 37 strain of RSV would infect
perinatal lambs and produce clinical disease similar to that in human infants. Perinatal (3- to 5-day-old) lambs
were inoculated intranasally with 2 mL/nostril of 1×105 focus-forming units (FFU)/mL (n=2) or 2.1×108
FFU/mL (n=3) of RSV Memphis 37. Clinical signs, gross and histological lesions, and immune and
inflammatory responses were assessed. Memphis 37 caused moderate to severe gross and histologic lesions
along with increased mRNA expression of macrophage inflammatory protein. Clinically, four of the five
infected lambs had a mild to severe increase in expiratory effort. Intranasally administered RSV strain
Memphis 37 infects neonatal lambs with gross, histologic, and immune responses similar to those observed in
human infants.
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Abstract
Respiratory syncytial virus (RSV) is the leading cause of hospitalization due to respiratory illness among infants
and young children of industrialized countries. There is a lack of understanding of the severe disease mechanisms
as well as limited treatment options, none of which are fully satisfactory. This is partly due to lack of a relevant
animal model of perinatal RSV infection that mimics moderate to severe disease in infants. We and others have
shown mild disease in perinatal lambs with either a bovine or a human A2 strain of RSV. The Memphis 37 clin-
ical strain of human RSV has been used to produce mild to moderate upper respiratory disease in healthy adult
volunteers. We hypothesized that the Memphis 37 strain of RSV would infect perinatal lambs and produce clin-
ical disease similar to that in human infants. Perinatal (3- to 5-day-old) lambs were inoculated intranasally with
2mL/nostril of 1· 105 focus-forming units (FFU)/mL (n= 2) or 2.1· 108 FFU/mL (n= 3) of RSV Memphis 37.
Clinical signs, gross and histological lesions, and immune and inflammatory responses were assessed. Memphis
37 caused moderate to severe gross and histologic lesions along with increased mRNA expression of macrophage
inflammatory protein. Clinically, four of the five infected lambs had a mild to severe increase in expiratory effort.
Intranasally administered RSV strain Memphis 37 infects neonatal lambs with gross, histologic, and immune re-
sponses similar to those observed in human infants.
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Introduction
Respiratory syncytial virus (RSV) is an envelopedRNA virus in the Paramyxoviridae family that causes
variable levels of disease severity in all age groups from in-
fants to the aged. Most commonly, RSV causes a mild upper
or lower respiratory disease with cold-like symptoms, but in
a small percentage of patients, particularly the very young,
severe disease can occur. Nearly every child in the United
States has been infected with RSV at least once by age 2
years.1 Because of its ubiquity, even the low percentage of
individuals that develop severe disease yields a significant
number of hospital cases. In the United States, 85,000–
144,000 infants with RSV infection are hospitalized annual-
ly.2 This constitutes 20%–25% of the pneumonia cases and
up to 70% of all bronchiolitis cases in the hospital.3,4
Current treatment of RSV infection is limited to supportive
care and one of two therapies approved by the U.S. Food and
Drug Administration that include either an inhaled nucleoside
analog (Ribavirin) with limited treatment efficacy or a prophy-
lactic monoclonal antibody (palivizumab), which is limited to
use in high-risk infants.5 Twomajor stumbling blocks in the de-
velopment of preventative and treatment regimens have been
the disastrous initial vaccine clinical trial6 and the lack of an
available, clinically relevant model of RSV infection. Rodents
are a valuable model of RSV infection but undergo postnatal al-
veolar development as opposed to the prenatal alveologenesis
that occurs in humans and sheep.7–9 Additionally, sheep and
humans share a number of upper and lower airway traits, in-
cluding airway branching pattern, nasal lymphoid tissue distri-
bution, alveolar size, submucosal gland type and distribution,
cartilage distribution, sensory nerves, airway capillary physiol-
ogy, mast cell distribution, mucus-secreting cells, number of
Clara cells in bronchioles, histamine effects, and cough/wheeze
response.10 Natural RSV disease occurs in cattle and sheep with
bovine respiratory syncytial virus (bRSV) and has a similar pre-
sentation: seasonal outbreaks of highly contagious, mild respi-
ratory disease with infrequent severe disease that occurs in
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conjunction with other pathogens.11,12 A bovine model of RSV
infection has been used by a number of groups and is useful in
mimicking human disease, but it is somewhat limited by the
cost of feed and housing and the typical birth of a single off-
spring in cattle. In addition, relatively large quantities of testing
material (therapeutic compounds) are required due to the size of
testing animals that may not be easily available at the preclini-
cal stage of drug development. Finally, there is current use of a
number of efficacious vaccines that decrease the severity of dis-
ease due to RSV in cattle, as opposed to the current situation in
humans.11 Sheep are a particularly attractive model because of
their smaller size, reduced cost, and increased offspring/parity
compared with cattle, and more a human-relevant pulmonary
development and structure compared with rodents. Also, new-
born and preterm lambs have increased RSV disease severity
compared with older lambs,13–15 and the histopathology of
RSV lesions in lambs (and cattle) is similar to that seen in
human infants.13,16 Also, lambs can be deprived of colostrum,
thus avoiding the effects of maternal antibodies.
In this study, perinatal lambs were intranasally inoculated
with human RSV (hRSV) Memphis strain 37 (M37) by using
an atomizer. This intranasal route was used to more closely
mimic natural disease. A similar method has been used to
cause upper airway disease in humans with M37.17 Previ-
ously, our group has administered virus (bRSV or hRSV
A2 strain) intratracheally or intrabronchially.15,18,19 It was
our hypothesis that a more physiological intranasal inocula-
tion of M37 hRSV would produce clinical disease and pa-
thology paralleling that in human neonates. Our results
demonstrate that M37 can cause consistent, moderate disease
at 6 days post inoculation (p.i.). Gross and microscopic le-
sions were similar to those reported in human infants, as
was the clinical expiratory effort seen in the infected lambs.
Materials and Methods
Experimental design
Animal use and experimental procedures were approved
by Iowa State University’s Animal Care and Use Committee.
Pilot study. A pilot study was completed in order to deter-
mine the potential susceptibility of young lambs to hRSV
M37. The pilot study included four lambs (2–5 days of age).
One lamb was inoculated intranasally (2mL/nostril, 1· 106
focus-forming units [FFU]), and three were inoculated with
a fiberoptic bronchoscope. The bronchoscope was inserted
to the level of the mainstem bronchus just distal to the tracheal
bifurcation in two lambs, which received 8 or 17mL; the third
lamb received 10mL in the deep airway of the right cranial
lobe. Clinical features, including heart rate, respiratory rate
Table 1. Primer and Probe Sequences Used for Real-Time Reverse Transcription Quantitative
Polymerase Chain Reaction, 5¢ to 3¢
M37
hRSV
Fwd GCTCTTAGCAAAGTCAAGTTGAA
CGA
bRSV Fwd CAGTCAAGAATATTATGCTTGGT
CATG
Rev TGCTCCGTTGGATGGTGTATT Rev CCTAACTTTTGTGCATATTCATAG
ACTTC
Probe 6 FAM-ACACTCAAACAAGATCA
ACTTCTGTCATCCAGC-TAMRA
Probe 6FAM-CAACCTGTTCCATTTCTGCT
TGTACGCTG-TAMRA
CCSP Fwd CAGCCCTGACGAAGACATGA IFN-c Fwd TGGAGGACTTCAAAAGGCTGAT
Rev GGGTGTCTACCAGCGTCTTCA Rev GATGGCTTTGCGCTGGAT
Probe 6FAM-AGAGGCAACAAGTC
AG-MGBNFQ
Probe 6FAM-CAAATTCCGGTGGATGATCT
GC-TAMRA
SP-A Fwd TGACCCTTATGCTCCTCTGGAT TNF-a Fwd CAACCTGGGACACCCAGAAT
Rev GGGCTTCCAAGACAAACTTCCT Rev TCTCAAGGAACGTTGCGAAGT
Probe 6FAM-TGGCTTCTGGCCTCGAGTG
CG-TAMRA
Probe 6FAM-CAAGGGCCAGGGTTCTTACC
GGAA-TAMRA
IL-6 Fwd GCTGCTCCTGGTGATGACTTC TGF-b Fwd TGTGTTCGTCAGCTCTACATTGAC
Rev GGTGGTGTCATTTTTGAAATCTTCT Rev TAGCCCTTGGGTTCGTGAAT
Probe 6FAM-CTTTCCCTACC
CCGGGTCCCCTG-MBGNFQ
Probe 6FAM-TCCAGCCCAGGTCCTTCCGG
A-TAMRA
IL-8 Fwd TTCCAAGCTGGTCTGTTGCT MCP-1a Fwd GCTGTGATTTTCAAGACCATCCT
Rev TTGACAGAACTGCAGCTTCACA Rev GGCGTCCTGGACCCATTT
Probe 6FAM-CCGCTTTCCTGCT
CTCTGCAGCTC-TAMRA
Probe 6FAM-AAAGAGTTTTGTGCAGACCC
CAACC-TAMRA
IL-10 Fwd GTCGGAATGATCCAGTTTTACCT MIP-1a Fwd CAGCAGCCAGTGCTCCAA
Rev GTCAGGCCCATGGTTCTCA Rev ACCTGCCGGCCTTTTTTG
Probe 6FAM-AGGAGGTGATG
CCACAGG-MGBNFQ
Probe 6FAM-CCTGGTGTCATCTTCCAGA-
MGBNFQ
IFN-b Fwd TGGTTCTCCTGCTGTGTTTCTC RANTES Fwd TGCTTCTGCCTCCCCATATG
Rev CGTTGTTGGAATCGAAGCAA Rev GGGCGGGAGATATAGGCAAA
Probe 6FAM-ACCACAGCTCTTTCC
AGGAGCTACA-TAMRA
Probe 6FAM-CACCACGCCCTGCT-MGBNFQ
The following targets were assessed: M37, M37 strain of respiratory syncytial virus; bRSV, bovine respiratory syncytial virus; CC10,
Clara cell secretory protein; SP-A, surfactant protein A; IL-6, interleukin 6; IL-8, interleukin 8; IL-10, interleukin 10; MIP-1a, macrophage
inflammatory protein; MCP-1a, monocyte chemotactic protein; TNF-a, tumor necrosis factor alpha; IFN-b, interferon-b; IFN-c, interferon-c;
TGF-b, tumor growth factor-b; RANTES, regulated on activation normal T-cell expressed and secreted.
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and character, attitude, ocular or nasal discharge, body weight,
and body condition, were recorded daily, and lung tissues
were collected 6 days post-inoculation.
Intranasal study. Neonatal lambs (2–3 days of age) were
randomly assigned to three groups: a control group (n = 2), a
low-dose RSV inoculated group (n = 2), and a high-dose
RSVinoculatedgroup(n= 3). Each lamb received 2mL/nostril
of inoculum administered via a syringe attached to a mucosal
atomization device (Wolfe Tory Medical, Inc., Salt Lake
City, UT). Control lambs were inoculated with cell growth
media; low-dose lambs were inoculated with M37 hRSV
grown in HEp-2 cells at 1 · 105 FFU/mL; high-dose lambs
were inoculated with the same virus (M37 hRSV in HEp-2
cells) at 2.1 · 108 FFU/mL. Viral inocula were provided by
Meridian Life Science (Memphis, TN), originally isolated
from a severe clinical case of RSV in an infant and main-
tained at low passage. Virus was obtained from Meridian
Life Science at passage 5, and a seed stock of passage
6 was made and frozen in aliquots. Passage 8 was used for
inoculation of lambs. Lambs were given daily antibiotics
(Ceftiofur, Pfizer, New York, NY; 1–2mg/kg, intramuscular)
to prevent secondary bacterial infection. Lambs were moni-
tored daily for clinical signs of respiratory disease and over-
all health, including heart rate, respiratory rate and character,
rectal temperature, attitude, ocular or nasal discharge, body
weight, and body condition. Animals were euthanized by so-
dium pentobarbital (Beuthanasia, Schering Plough Animal
Health, Union, NJ) overdose on day 6 p.i.
Postmortem
After euthanasia the thorax was opened, lungs were re-
moved, and gross lesionswere scored as described previously20
and photographed ex vivo. Tissue samples were collected from
each lung lobe of all animals in the same manner, with uni-
form sampling of each lobe. Briefly, three samples from
each lobe were snap frozen in liquid nitrogen for reverse tran-
scription quantitative polymerase chain reaction (RT-qPCR),
two samples from each lobe were placed in tissue cassettes
and put in 10% neutral-buffered formalin for histological
and immunohistochemical analysis.
RT-qPCR
Whole vials of right and left cranial, right and left middle,
and accessory lobes were homogenized in TRIzol (Invitrogen,
Carlsbad, CA), then pooled for each animal to create a compos-
ite slurry. RNA isolation continued per manufacturer’s instruc-
tions (Invitrogen), followed by DNase treatment (Ambion,
TURBO DNase, Austin, TX), then diluted 1:10 with a combi-
nation of RNaseOUT (Invitrogen) and nuclease-free water
(Invitrogen). Spectrophotometry (NanoDrop, Thermo Scien-
tific, Waltham, MA) was used to assess each sample for purity
and quantity. RNA integrity numbers>7.5 were routinely
obtained by Bioanalyzer 2100 for all RNA samples. Hydrolysis
probe-based RT-qPCR was carried out using One-Step Fast
qRT-PCR Kit with ROX master mix (Quanta, BioScience,
Gaithersburg, MD) in a GeneAmp 5700 Sequence Detection
System (Applied Biosystems, Carlsbad, CA) employing PRE-
XCEL-Q for all set-up calculations.21 Primer and probe se-
quences for all targets (Table 1) have been previously used in
our lab. All sequences were generated using ABI Primer
Express 2.0 software. All samples were diluted to achieve a
final RT-qPCR concentration of 0.7844 ng/lL. Each sample
was assessed in duplicate and each target gene amplification
Cq converted to a relative quantity (rQ) based on the following
equation: rQ=10[(Cq  b)/m], where Cq is the target quantifica-
tion cycle, and b and m are the y-intercept and slope, respec-
tively, from the Stock I (sample mixture)–derived standard
curve for each target.21 Additionally, the RSV Cq values
were used to estimate viral copy number per milligram of
lung tissue using a virtual absolute plasmid standard curve.
This standard curve was estimated four times with plasmid
constructs on a GeneAmp 5700 SDS using qScript One-Step
Fast qRT-PCR kit with ROX mastermix; establishing an
NCq value of 1.4516· 1011 amplicons generated at Cq at a
fixed DRn RFU threshold of 0.04. The Stock I–derived stan-
dard curve for RSVM37 indicated an amplification efficiency
of 99.61%, while the virtual plasmid absolute standard curve
was assigned an amplification efficiency of 100%.
FIG. 1. Clinical data of lambs infected with human respi-
ratory syncytial virus (hRSV) strain Memphis 37 (M37). (A)
Lambs receiving the high-dose (4.2 · 108 focus-forming
units [FFU]) of virus inoculum had a significantly higher
clinical expiratory effort score than control or low-dose
lambs on days 5 and 6 by two-way ANOVA (**). Expiratory
effort score was assessed as follows: 0 = no effort; 1 =first
detectable prolonged exhale; 2 = prolonged > 1 sec, slight
abdominal effort; 3 = prolonged to > 3 sec, hard abdominal
effort. (B) Cumulative weight gain over the study period
was significantly lower for the high-dose group than either
the control or low-dose group.
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Gross lesion evaluation and scoring
After removal, percentage parenchymal involvement was
estimated for each lung lobe. Percentages were converted
to a scale using the following formula: 0%= 0; 1%–9% = 1;
10%–39% = 2; 40%–69% = 3; 70%–100% = 4. Group aver-
ages were calculated for the gross lesion score.
Histologic evaluation and scoring
Ahistologic score was given by determining percent consol-
idation followed by conversion to a consolidation scale used by
our laboratory previously20: 0% consolidation= 0; 1%–9%
consolidation= 1; 10%–39% consolidation= 2; 40%–69%
consolidation= 3; 70%–100% consolidation= 4. Group aver-
ages were calculated for the alveolar consolidation score.
Immunohistochemistry
Immunohistochemistry for RSV antigen was performed on
paraffin-embedded tissue as described previously,19 with the
following variations: instead of Pronase E antigen retrieval,
heated buffer antigen retrieval was performed in pH 9.0
Tris-EDTA buffer containing 0.05% Tween 20, with micro-
wave heating just to boiling followed by 30min in a pre-
warmed steamer and cooling for 5min on ice. Primary
polyclonal goat anti-RSV antibody (BioDesign/Meridian,
San Ramon, CA) was applied for 2 h at room temperature
(*20C) at a concentration of 1:300 instead of 1:50 as previ-
ously described. Color was developed using Nova Red
(Vector, Burlingame, CA), counterstaining with Harris’ hema-
toxylin, after which slides were dehydrated and cover-slipped.
Slides were then scored by the following method: twenty
10·fields on each slide containing two pieces of lung were
assessed for antigen staining. Immunoreactive (IR) cells
were counted, then converted to a score where 0 (IR)= 0;
1–10 (IR)= 1; 11–39 (IR)= 2; 40–99 (IR)= 3; and ‡ 100
(IR)= 4. The number of fields per slide with antigen staining
was also recorded. Composite numbers for both number of
fields with antigen staining and score were assessed.
Statistical analysis
All analyses were performed using GraphPad Prism 5
(GraphPad Software, Inc., LaJolla, CA). All postmortem data
were assessed with one-way ANOVA followed by Tukey’s
post-test. All clinical data were assessed with two-way
ANOVA, and cumulative weight change was additionally
assessed with one-way ANOVA followed by Tukey’s post-test.
Results
Pilot study
At day 6 p.i., all four lambs had gross and microscopic lung
pathology (epithelial degeneration and syncytia; neutrophils
and debris in bronchioles/alveoli; lymphocytic infiltrates). Inoc-
ulation intranasally (2mL/nostril) produced bilateral lung
FIG. 2. Representative
gross lesions and scoring of
lesions caused by M37 hRSV
in lambs. (A) Control lamb
lung. (B) Low-dose (2 · 105
FFU) lamb lung. (C) High-
dose (4.2· 108 FFU) (arrows
indicate lesions). (D) Lesion
scores. The scoring scale is
based on percent lung in-
volvement for each lobe:
0% = 0; 1%–9% = 1; 10%–
39%= 2; 40%–69%= 3;
70%–100%= 4. Lesion score
in the high-dose group (n = 3)
is significantly higher than
either control group (n = 2) or
low-dose group (n = 2), low-
dose score is significantly
higher than control group;
ANOVA, followed by
Tukey’s, p < 0.05.
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lesions. Lambs inoculated directly into mainstem bronchus (8
or 17mL) or into deep airway (10mL) produced local lesions
that were intense, occupying 60%–90% of the lung lobe.
Daily body temperature was significantly higher (39.0C vs.
39.8C) at day 4 p.i. than at day 0. One lamb had mildly in-
creased expiratory effort on days 4–6 p.i. Histologic lesions
were present in all infected lambs and were similar to those de-
scribed previously for RSV in lambs.13,15 Briefly, lambs had
bronchiolitis with multifocal bronchiolar epithelial cell necrosis
and mild to moderate hyperplasia of nearby epithelial cells;
intraluminal infiltrates of neutrophils, the presence of occa-
sional syncytial cells, and accumulation of cell debris within
bronchioles; mild to moderate peribronchiolar infiltrates of
lymphocytes and plasma cells in the adventitia; mild to moder-
ate alveolar type II cell hyperplasia; and minimal intraseptal in-
filtrates of lymphocytes.
Intranasal study
Clinical and postmortem findings. In the group infected
with a high-dose inoculum, all three lambs had increased ex-
piratory effort (i.e., forced expiration, abdominal breathing),
first observed on day 1 in one lamb, and then noted in all
three subjects by day 4. Group score averages for the high-
dose group were significantly higher than control (0) on
days 5 and 6 p.i. (Fig. 1). While there was no difference in
weight gain on any given day, total weight gain in the
high-dose group was significantly lower than either the con-
trol or low-dose group. No significant difference in weight
gain was noted between the control and low-dose groups
(Fig. 1). There were no significant changes in any other clin-
ical parameters. All five infected lambs had multifocally to
locally extensive dark red, well-demarcated foci of pulmo-
nary consolidation, which varied in severity from moderate
to severe (Fig. 2). These were slightly firm to rubbery on pal-
pation. The three high-dose lambs had more extensive le-
sions than the two low-dose lambs on a basis of percentage
tissue involvement. Gross lesion scores (based on percent-
age of lung parenchyma involved) of the high-dose group
were significantly higher than either the control or low-
dose group (Fig. 2).
Histopathology. Infected lambs had multifocal to conflu-
ent foci of cellular infiltrate that filled bronchioles and
alveoli and expanded the alveolar interstitium consistent
with RSV infection reported previously in lambs.13,20 This
infiltrate was composed of lymphocytes, neutrophils, macro-
phages, and plasma cells. Bronchioles and alveoli contained
moderate to abundant amounts of sloughed, degenerate epi-
thelial cells and neutrophils. Large epithelial syncytial cells
were numerous within bronchioles. Pulmonary epithelium
FIG. 3. Representative
histologic lesions and scoring
of lesions caused by M37
hRSV in lambs. (A) Control
lamb lung with normal
alveoli and bronchioles,
20 ·magnification. (B) High-
dose lamb with characteristic
inflammation including neu-
trophils and sloughed epithe-
lia cells in bronchioles and
alveolar septa infiltrated by
macrophages, lymphocytes,
and fewer neutrophils with
syncytial cells (arrow),
20 ·magnification. (C)
40 · view of characteristic
histopathology. (D) Histo-
logic lesion scores; the his-
tologic score of the high-dose
group is significantly higher
than either control group or
low-dose group; ANOVA,
followed by Tukey’s,
p < 0.05.
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lining affected airways was thickened in areas by plump cu-
boidal cells with oval, vesiculate nuclei (type II pneumocyte
hyperplasia). Scoring of the histologic sections yielded a sig-
nificantly higher score ( p< 0.05) in high-dose lambs (3.19)
than either control (0.07) or low-dose group (0.86) (Fig. 3).
Immunohistochemistry. Control lambs lacked staining
for RSV antigen, while all low-dose and high-dose lambs
had cells with immunoreactivity for RSV antigen present
in areas of consolidation (Fig. 4). Antigen was present in
epithelial cells lining alveoli and bronchioles and within
the cytoplasm of occasional macrophages. Scoring of the his-
tologic sections yielded both a higher overall score per ani-
mal as well as a greater number of total fields with
immunoreactive cells per animal in the high-dose group.
Quantification of virus. Lung homogenates from each an-
imal were assessed by RT-qPCR for relative mRNA levels.
As expected, control animals lacked expression of RSV
RNA. In contrast, the presence of RSV RNA was detected
in lung homogenates of all infected animals. The mean
RSV RNA level in lungs of the high-dose animals was 2.9-
fold higher than that of the low-dose animals (Fig. 5a). The
difference in the RSV RNA levels between the low- and
high-dose animals was not statistically significant
( p > 0.05). Lung samples from each animal were also
assessed for the presence of bRSV by the same RT-qPCR
method as for other targets and primer and probe sequence
used in previous studies on bRSV in lambs.18,22 The analysis
demonstrated a lack of signal in all animal groups (not
shown), indicating that the lambs did not acquire bRSV in-
fection naturally.
Lung cytokine gene expression by RT-qPCR. The quan-
titative PCR analysis demonstrated that the high-dose group
had significantly higher level of expression of macrophage
inflammatory protein (MIP)-1a in lung tissue compared to
the uninfected control group or low-dose group (Fig. 5b).
Discussion
Intranasal inoculation with the M37 strain of RSV yielded
dose-dependent clinical expiratory effort scores, gross le-
sions, histologic lesions, and altered immune gene expres-
sion as assessed by RT-qPCR in infected lambs. Because
this same viral strain causes sinusitis and clinical signs in
normal human subjects following an experimental chal-
lenge,17 infection in lambs allows mechanistic investigations
that could improve understanding of RSV disease in humans.
Also, the model could be used for the assessment of thera-
peutic antiviral compounds or vaccines developed specifi-
cally for human strains of RSV.
Previously, we have assessed a broad range of these genes
in term lambs infected with RSV A2 strain and identified
FIG. 4. Representative im-
munohistochemistry (A, B)
and scoring of antigen im-
munoreactivity (C, D) in
lambs infected with M37
hRSV. (A) Control lamb lung
(20 · ). (B) Lung from a lamb
receiving high-dose RSV
with abundant intracellular
staining (20· ). Inset,
40 ·magnification. (C) Total
number of fields with immu-
noreactivity for RSV antigen/
animal for which 20 (10· )
fields were assessed for each
lung slide. Each slide con-
tained two sections (minimum
of 1 cm by 1 cm dimension)
of lung from a lobe; all seven
lobes of each animal were
examined. The low-dose and
high-dose groups were sig-
nificantly different from the
control and each other;
ANOVA, followed by
Tukey’s, p < 0.05. (D) Slides
scored by number of immu-
noreactive cells per field. The
high-dose group had a sig-
nificantly higher score than
the control group; ANOVA,
followed by Tukey’s,
p < 0.05.
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mRNA increases in interferon (IFN)-c, interleukin (IL)-8,
monocyte chemotactic protein (MCP)-1a, and programmed
cell death 1 ligand 1 (PD-L1), and decreases in IFN-b, IL-
10, and tumor growth factor (TGF)-b.23 While immune
and inflammatory genes explored were not exhaustive in
the present study, those analyzed have been reported to be al-
tered in human disease and include TNF-a, IL-6, IL-8, MIP-
1a, RANTES, MCP-1a, and limited IFN-c.24–26 The results
of this study showed an increase in MIP-1a in animals
infected with the high dose of M37. Additionally, while
IL-8 was not statistically elevated in infected animals, con-
trol animals completely lacked signal, while high-dose ani-
mals all had detectable signal. There was a trend of
increased expression of RANTES, MCP-1a, and IFN-c in
the high-dose group, though statistical significance at
p < 0.05 was not achieved. Previous studies in lambs have
shown limited changes in these chemokines, while marked
changes in these chemokines have been reported in RSV-
infected infants.23,24 Limited sample sizes (two or three ani-
mals) in this study may underestimate significant differences
between groups. Also, a lack of increased TNF-a or IL-6 in
this study could be due to the sampling time point. We chose
day 6 p.i. because previous studies have shown this to be a
good time point for peak gross and histologic lesions,
while increases in TNF-a or IL-6 tend to occur early in the
course of disease (day 3 p.i.) in lambs infected with hRSV
A2 strain.23 Measurement of cytokine expression during
the course of infection could be valuable in understanding
the immune response with an eventual goal of altering that
response to abrogate infection and improve clinical outcome.
Viral load as assessed in postmortem lung tissue by RT-
qPCR was shown to peak at day 6 p.i. in our previous studies
in lambs.20 By RT-qPCR we had no detectable RSV RNA in
control lambs, while all infected lambs showed significant
RSV RNA levels. Day 6 p.i. termination point was selected
because it provides time to collect additional clinical data
and allows for the development of peak gross and histologic
lesions as well as increased levels of viral RNA. For exam-
ple, increased expiratory effort was first detected at day 1
and worsened by days 5 and 6. Earlier time points may be
better for M37 virus isolation as shown in studies in mouse
and cotton rat models in which RSV replication often
peaks at day 3 and 4 p.i.27,28 Additional information on the
correlation between viral shedding and clinical symptoms
would aid in understanding the kinetics of RSV infection.
Nasal swabs were taken daily and stored in saline with su-
crose but did not yield virus upon culture (data not shown).
In subsequent experiments, our protocol for postmortem
broncho alveolar lavage fluid (BALF) viral titers has been
modified with great success; thus, lack of viral titers in the
nasal swabs of these animals may be due to method and
not lack of shedding. Future studies may use this modified
protocol on daily nasal swabs. Additional procedures such
as antemortem BALF collection may be of value as well.
Previous work in our lab with the RSV A2 strain yielded
significant changes in body temperature but did not show
markedly increased expiratory effort or as extensive gross le-
sions as observed in this study.20 Differences between this
study with RSV strain M37 and the previous study using in-
fection with RSV strain A2 include a 10-fold higher inocula-
tion viral titer (in the high-dose group) and intranasal versus
intrabronchial inoculation. The intranasal route of inocula-
tion used with M37 in this study may be more reflective of
natural infection than intrabronchial inoculation as used in
our A2 studies. Also, intranasal inoculation avoids sedation,
which alters airflow and breathing as well as the inherent
risk, albeit small, involved in any sedation technique. The
drawback is that even small changes in head or body posi-
tion, overall animal sizes, and natural variations in upper re-
spiratory physiology can yield a more variable distribution of
virus to the lung, and thus a very different pattern of gross
and histologic lesion distribution. Overall, in this study
there was a more diffuse pattern of lesions as compared to pre-
vious studies employing intrabronchial inoculations with a
fiberoptic bronchoscope or intratracheal inoculation.15,20 Stud-
ies to verify the greater virulence of M37 versus A2 among
different inoculation methods would strengthen this model.
FIG. 5. (A) M37 gene expression analysis in postmortem
lung tissue by quantitative polymerase chain reaction
(PCR). M37 RNA was present in all infected animals and
none of the controls. The data are presented as RNA relative
to the standard curve. (B) Cytokine gene expression analysis
in postmortem lung tissue by quantitative PCR mRNA levels
were significantly higher in lambs receiving the high dose of
M37 than either control or low-dose group for macrophage
inflammatory protein (MIP-1a), as indicated by *. The data
are presented as estimated copy number based on a virtual
absolute plasmid standard curve. One-way ANOVA, fol-
lowed by Tukey’s method, p < 0.05. Data are presented as
relative to high-dose lambs.
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FIG. 5. (Continued).
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Route of inoculation (nebulized, intranasal, intratracheal,
intrabronchial), viral dose and dilution, as well as lamb fac-
tors such as vendor source, colostrum deprivation, preterm
birth, or age at inoculation can all be adjusted with the
goal to create low-cost, manageable, and reproducible mod-
els of moderate and severe RSV disease. Similar to our pre-
vious studies using RSV A2 strain, lambs in this study
received colostrum and therefore may have had maternally
derived bRSV-specific serum antibodies. Colostrum depriva-
tion was not attempted due to the potentially higher health
risk of these animals and also because RSV A2 strains caused
significant disease without colostrum deprivation.20 How-
ever, subsequent studies in our laboratory have used colos-
trum-deprived lambs.29,30 Ideally, a separate study would
be performed comparing colostrum-fed and colostrum-
deprived lambs’ responses to RSV, with additional measure
of serum antibody and overall health possibly being helpful
in determining the extent to which these antibodies affect
hRSV disease in lambs. Colostrum-deprived calves have
lower viability and increased complications compared to co-
lostrum-fed calves,31 and colostrum-deprived lambs exhibit
decreased growth.32
Similar to humans, natural disease in cattle is more com-
mon in young animals (1–6 months) than in neonates. Com-
paring disease between newborn and older (6-week-old)
calves, neonates shed virus longer and had more severe pa-
thology, while clinical disease was less severe and pro-
inflammatory cytokine levels were lower.33 In experimental
infection of lambs with bRSV, greater lesion severity has
been observed in 1-week-old compared to 6-month-old
lambs.13,14 In a preterm lamb model, lesions were more se-
vere in preterm compared to full-term lambs.15 While the
majority of cases of RSV occur in children 6 months to 2
years of age, infants < 6 months of age are at increased
risk of severe disease, and prematurity is an additional, inde-
pendent risk factor.34 A neonatal model is necessary to un-
derstand why clinical disease is less common, but severe
disease more prevalent in this unique population. Acquiring
lambs at a very young age provides insight to RSV in a spe-
cific, at-risk demographic and potentially limits their expo-
sure to pathogens that could interfere with infection. A
comparison of preterm, full-term, and older-age lambs has
great potential to better understand the implications of age
on disease outcome. Infection of healthy, full-term lambs
presented an ideal starting point for these studies with a
balance of potential for severe disease and applicability of
design.
The data here demonstrate the capacity of a human clinical
isolate of RSV used for human experimental infection to rep-
licate and cause disease in lambs. The M37 strain of RSV can
be used in lambs to produce moderate respiratory disease and
has the potential to be a model of more severe disease than
the A2 strain. Further investigation of these viruses in direct
comparison is needed to discern differences in disease dy-
namics between the two strains.
Overall, lambs closely parallel human infant disease char-
acteristics in clinical course, gross and histologic lesions, and
inflammatory cytokine profile at key time points in disease.
Also, lambs can be born preterm (90% gestation) and survive
for experimentation, which allows assessment of RSV infec-
tion in preterm lung. Further exploration at multiple time
points and expansion of data points can be pursued not
only to better understand the disease, but also to assess re-
sponse to novel therapeutic or prophylactic agents as well as
vaccines in this model of disease. This study strengthens the
lamb model by establishing infection and disease progression
with a new human strain of RSV that is expected to be exten-
sively used in the human experimental infection to obtain clin-
ical proof of concepts for novel treatment approaches.
Therefore, the lamb RSV M37 model holds great promise to
facilitate the optimization, preclinical development, and selec-
tion of novel agents for the advancement into clinical studies.
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Abbreviations Used
BALF¼ broncho alveolar lavage fluid
bRSV¼ bovine respiratory syncytial virus
FFU¼ focus-forming units
hRSV¼ human respiratory syncytial virus
IFN¼ interferon
IL¼ interleukin
IR¼ immunoreactive
M37¼Memphis strain 37
MCP¼monocyte chemotactic protein
MIP¼macrophage inflammatory protein
p.i.¼ post inoculation
rQ¼ relative quantity
RSV¼ respiratory syncytial virus
RT-qPCR¼ reverse transcription quantitative
polymerase chain reaction
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